缩写名/全名 |
J IMMUNOTHER CANCER
Journal for ImmunoTherapy of Cancer |
||||||||||||||||||||||||||||||||||||
ISSN号 | 2051-1426 | ||||||||||||||||||||||||||||||||||||
研究方向 | - | ||||||||||||||||||||||||||||||||||||
影响因子 | 2015:0, 2016:0, 2017:8.374, 2018:8.676, 2019:9.913, | ||||||||||||||||||||||||||||||||||||
出版国家 | UNITED STATES | ||||||||||||||||||||||||||||||||||||
出版周期 | |||||||||||||||||||||||||||||||||||||
年文章数 | 326 | ||||||||||||||||||||||||||||||||||||
出版年份 | 0 | ||||||||||||||||||||||||||||||||||||
是否OA | Yes | ||||||||||||||||||||||||||||||||||||
审稿周期(仅供参考) | |||||||||||||||||||||||||||||||||||||
录用比例 | |||||||||||||||||||||||||||||||||||||
投稿链接 | https://jitc.biomedcentral.com/submission-guidelines | ||||||||||||||||||||||||||||||||||||
投稿官网 | https://jitc.biomedcentral.com/ | ||||||||||||||||||||||||||||||||||||
h-index | 36 | ||||||||||||||||||||||||||||||||||||
CiteScore |
|
||||||||||||||||||||||||||||||||||||
PubMed Central (PMC)链接 | http://www.ncbi.nlm.nih.gov/nlmcatalog?term=2051-1426%5BISSN%5D | ||||||||||||||||||||||||||||||||||||
中科院SCI期刊分区 ( 2018年新版本) |
|
||||||||||||||||||||||||||||||||||||
中科院SCI期刊分区 ( 2020年新版本) |
|
中国学者近期发表的论文 | |
1. | HHLA2 in intrahepatic cholangiocarcinoma: an immune checkpoint with prognostic significance and wider expression compared with PD-L1 Author: Chu-Yu Jing, Yi-Peng Fu, Yong Yi, Mei-Xia Zhang, Su-Su Zheng, Jin-Long Huang, Wei Gan, Xin Xu, Jia-Jia Lin, Juan Zhang, Shuang-Jian Qiu, Bo-Heng Zhang Journal: Journal for ImmunoTherapy of Cancer, 2019, Vol.7, , DOI:10.1186/s40425-019-0554-8 DOI |
2. | Increased intratumoral mast cells foster immune suppression and gastric cancer progression through TNF-α-PD-L1 pathway Author: Yipin Lv, Yongliang Zhao, Xianhua Wang, Na Chen, Fangyuan Mao, Yongsheng Teng, Tingting Wang, Liusheng Peng, Jinyu Zhang, Ping Cheng, Yugang Liu, Hui Kong, Weisan Chen, Chuanjie Hao, Bin Han, Qiang Ma, Quanming Zou, Jun Chen, Yuan Zhuang Journal: Journal for ImmunoTherapy of Cancer, 2019, Vol.7, , DOI:10.1186/s40425-019-0530-3 DOI |
3. | A good response of refractory mantel cell lymphoma to haploidentical CAR T cell therapy after failure of autologous CAR T cell therapy Author: Tongjuan Li, Yuanyuan Zhang, Dan Peng, Xia Mao, Xiaoxi Zhou, Jianfeng Zhou Journal: Journal for ImmunoTherapy of Cancer, 2019, Vol.7, , DOI:10.1186/s40425-019-0529-9 DOI |
4. | Therapeutic efficacy, pharmacokinetic profiles, and toxicological activities of humanized antibody-drug conjugate Zt/g4-MMAE targeting RON receptor tyrosine kinase for cancer therapy Author: Hang-Ping Yao, Liang Feng, Sreedhar Reddy Suthe, Ling-Hui Chen, Tian-Hao Weng, Chen-Yu Hu, Eun Sung Jun, Zhi-Gang Wu, Wei-Lin Wang, Song Cheol Kim, Xiang-Min Tong, Ming-Hai Wang Journal: Journal for ImmunoTherapy of Cancer, 2019, Vol.7, , DOI:10.1186/s40425-019-0525-0 DOI |
5. | Cancer-cell-secreted CXCL11 promoted CD8<Superscript>+</Superscript> T cells infiltration through docetaxel-induced-release of HMGB1 in NSCLC Author: Qun Gao, Shumin Wang, Xinfeng Chen, Shaoyan Cheng, Zhen Zhang, Feng Li, Lan Huang, Yang Yang, Bin Zhou, Dongli Yue, Dan Wang, Ling Cao, Nomathamsanqa Resegofetse Maimela, Bin Zhang, Jane Yu, Liping Wang, Yi Zhang Journal: Journal for ImmunoTherapy of Cancer, 2019, Vol.7, , DOI:10.1186/s40425-019-0511-6 DOI |
6. | Allogenic Vγ9Vδ2 T cell as new potential immunotherapy drug for solid tumor: a case study for cholangiocarcinoma Author: Mohammed Alnaggar, Yan Xu, Jingxia Li, Junyi He, Jibing Chen, Man Li, Qingling Wu, Li Lin, Yingqing Liang, Xiaohua Wang, Jiawei Li, Yi Hu, Yan Chen, Kecheng Xu, Yangzhe Wu, Zhinan Yin Journal: Journal for ImmunoTherapy of Cancer, 2019, Vol.7, , DOI:10.1186/s40425-019-0501-8 DOI |
7. | TNF-α enhances Th9 cell differentiation and antitumor immunity via TNFR2-dependent pathways Author: Yuxue Jiang, Jintong Chen, Enguang Bi, Yinghua Zhao, Tianxue Qin, Yiming Wang, Alison Wang, Sujun Gao, Qing Yi, Siqing Wang Journal: Journal for ImmunoTherapy of Cancer, 2019, Vol.7, , DOI:10.1186/s40425-018-0494-8 DOI |
8. | Correction to: Serious adverse events and fatal adverse events associated with nivolumab treatment in cancer patients Author: Bin Zhao, Hong Zhao, Jiaxin Zhao Journal: Journal for ImmunoTherapy of Cancer, 2019, Vol.7, , DOI:10.1186/s40425-018-0487-7 DOI |
9. | Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis Author: Yixin Zhou, Chen Chen, Xuanye Zhang, Sha Fu, Cong Xue, Yuxiang Ma, Wenfeng Fang, Yunpeng Yang, Xue Hou, Yan Huang, Hongyun Zhao, Shaodong Hong, Li Zhang Journal: Journal for ImmunoTherapy of Cancer, 2018, Vol.6, , DOI:10.1186/s40425-018-0477-9 DOI |
10. | 1-Pyrroline-5-carboxylate released by prostate Cancer cell inhibit T cell proliferation and function by targeting SHP1/cytochrome c oxidoreductase/ROS Axis Author: Yutao Yan, Lei Chang, Hongzhe Tian, Lu Wang, Yawei Zhang, Tao Yang, Guohao Li, Weifeng Hu, Kavita Shah, Gang Chen, Yonglian Guo Journal: Journal for ImmunoTherapy of Cancer, 2018, Vol.6, , DOI:10.1186/s40425-018-0466-z DOI |
|
|